United Therapeutics (NASDAQ:UTHR) reported Q4 2017 earnings this Morning, coming in at $0.43 per share, missing Wall Street’s estimates of $3.59 per Share. Revenue for the quarter came in at $464.70 million beating analyst estimates of $420.55 million Recent Insider Trading for United Therapeutics (NASDAQ:UTHR)
- On 12/8/2017 Martine A Rothblatt, CEO, sold 1 with an average share price of $136.16 per share and the total transaction amounting to $136.16.
- On 12/7/2017 Christopher Causey, Director, sold 580 with an average share price of $134.72 per share and the total transaction amounting to $78,137.60.
- On 11/30/2017 Martine A Rothblatt, CEO, sold 1,241 with an average share price of $128.95 per share and the total transaction amounting to $160,026.95.
- On 11/24/2017 Martine A Rothblatt, CEO, sold 1,253 with an average share price of $124.07 per share and the total transaction amounting to $155,459.71.
- On 11/16/2017 Martine A Rothblatt, CEO, sold 7,061 with an average share price of $121.12 per share and the total transaction amounting to $855,228.32.
- On 11/9/2017 Martine A Rothblatt, CEO, sold 1,260 with an average share price of $121.46 per share and the total transaction amounting to $153,039.60.
Recent Trading for United Therapeutics (NASDAQ:UTHR) Shares of United Therapeutics closed the previous trading session at 134.12 down -0.84 0.62% with 134.125 shares trading hands.